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A commentary on
A breathing-based meditation intervention for patients with major depressive disorder 
following inadequate response to antidepressants: a randomized pilot study
by Sharma A, Barrett MS, Cucchiara AJ, Gooneratne NS, Thase ME. J Clin Psychiatry (2017) 
78(1):e59–63. doi: 10.4088/JCP.16m10819
Recently, the American College of Physicians published clinical practice guidelines recommending 
yoga and other non-pharmacological modalities as non-invasive therapies for patients with back 
pain (1). Whether for back pain, depressive symptoms, or other chronic disorders, can we imagine 
doctors prescribing “breathing” and “yoga” together with pharmacotherapies? The answer may be 
forthcoming. An article by Sharma et al. (2) on non-pharmacological treatment of drug-resistant 
depression is a welcoming addition to growing clinical research on adjunct therapies where phar-
maceutical drugs may produce inadequate responses. Developing adjunct therapies that incorporate 
non-pharmacological and self-management practices offers means not only to improve therapy 
outcomes but also to maintain health-related quality of life after reaching remission. Since chroni-
cally ill patients, caregivers, and health-care providers embrace challenges of refractory medical 
conditions, medication non-adherence, and increasing treatment costs, clinical findings related to 
the drug-resistant depression described in Sharma et al. (2) have a broader impact on treatments of 
chronic diseases.
The Sharma et  al. article (2) reports clinical efficacy of the breathing-based practice called 
the Sudarshan Kriya Yoga (SKY) in patients with major depressive disorder (MDD) who did not 
respond to antidepressant drugs. SKY is a breathing-based meditative technique of slow, medium, 
and fast rhythmic breathing cycles, and it does not require meditation experience. The 8-week 
SKY yoga treatment consisted of intense, 1-week training and 6-session SKY practice (3.5 h/day), 
followed by 7 weeks of at-home practice (20–25 min/day) and once-a-week 1.5 h sessions. In this 
controlled study, 25 patients who were taking antidepressants were randomized to either the SKY 
or waitlist control groups. The primary endpoint was measured using the Hamilton Depression 
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Rating Scale (HDRS), and the secondary points were measured 
using the Beck Depression Inventory and the Beck Anxiety 
Inventory scores. Outcome measures were taken at least 1 week 
prior to the treatment (baseline), and at 1 and 2  months of 
the study. After 4 and 8  weeks of SKY treatment, significant 
improvements in depression symptoms were observed, as com-
pared to no changes in the waitlist group. For the intent-to-treat 
sample, 46% of patients had >50% reduction of HDRS score 
from baseline.
This is not the first report on clinical efficacy of SKY for the 
treatment of depressive symptoms (3–5); however, it is the first 
report on its effectiveness in patients who do not respond to anti-
depressants. The health-related effects and therapeutic potential 
of SKY were reviewed (6), and yoga-based interventions for 
mental health are supported by clinical evidence (7). A recent 
randomized study showed that mindfulness-based cognitive 
therapy was effective in patients with drug-resistant depres-
sion (8), consistent with previous findings (9). Noteworthy, the 
5-week Hatha yoga study did not indicate additional benefits for 
patients with MDD who were taking antidepressant drugs (10). 
Yoga is considered as safe if practiced properly, and with few 
possible adverse effects (11), supporting its potential as adjunc-
tive intervention, which may improve tolerability, compliance, 
and efficacy of concurrent treatments. While yoga and psycho-
therapy may appear attractive adjunct therapies for depression, 
more longitudinal studies are needed to optimize their clinical 
benefits.
Physiological effects of breathing meditation and yoga indicate 
their complex pleiotropic nature, while allowing to glean insight 
into possible antidepressant mechanisms. Research on neuronal 
mechanism of meditation techniques, including yoga, shows 
engagement of specific brain structures (e.g., anterior cingulate 
cortex) involved in autonomic cognitive and emotional regula-
tion (12–14). Three-month yoga intervention in patients with 
depression increased serum BDNF levels and decreased cortisol 
levels (15); this is in accord with yoga supporting stress regula-
tion through the hypothalamic–pituitary–adrenal axis (16). Yoga 
and breathing exercises can modulate specific brain waves, 
including increase in the alpha wave activity (17). Effects of yoga 
correlates with the amount of practice (18), further emphasizing 
the importance of “dosing” and total duration of yoga treatment 
for specific chronic medical conditions, for example, for back 
pain (19–22).
There are two broader aspects of the work of Sharma et  al. 
(2), namely: (1) growing number of clinical studies of diverse 
non-pharmacological modalities as adjunct treatments of CNS 
disorders and (2) developing non-pharmacological therapies 
as digital therapeutics using the “software-as-medical-device” 
strategy (Figure 1). With respect to the first aspect, nutrition and 
physical activity are promising adjunct therapies. Dietary and 
probiotic therapies can decrease depressive symptoms (23, 24), 
also in patients with MDD (25, 26). Folic acid was shown to be 
effective in refractory depression (27, 28). Both low- and high-
intensity physical activity can improve response to drug therapy 
for depression (29–31). Lower sertraline doses may be required 
in patients using physical activity (32). There is also an increas-
ing body of clinical evidence that ketogenic, modified Atkins and 
low-glycemic diets, or music, are beneficial for seizure control in 
FIGUre 1 | merging pharmacological and non-pharmacological interventions to improve patient engagement and therapy outcomes for depression 
and other CnS disorders. Brain imaging and physiological studies suggest several overlapping mechanisms for CNS drugs and non-pharmacological 
interventions such as yoga, mindfulness, breathing meditations, and exercises (13, 40, 41). Delivering non-pharmacological interventions through telemedicine and 
medical mobile apps (software as medical device) opens long-term prospects to integrate disease-specific self-care with pharmacotherapies using drug–device 
combination products. Companies such as WellDoc, Pear Therapeutics, or Akili Interactive advance development of digital therapeutics for diverse chronic medical 
conditions. Regulatory agencies are involved in ensuring the patient’s safety and clinical efficacy of medical mobile apps (42).
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patients with drug-resistant epilepsy (33–38). Mindfulness-based 
interventions are effective for substance use disorders (39).
With respect to the second broader aspect of the Sharma et al., 
mobile health (mHealth) technologies offer new opportunities 
for non-pharmacological modalities to be developed as adjunct 
therapies for the CNS disorders and delivered as drug–device 
combination products (43). There are several mobile apps and 
computer-based games that show clinical benefits in patients 
with depression (44–47). Given availability of mobile apps for 
deep breathing, yoga, nutrition, or physical exercise, it is feasible 
to integrate their contents in order to “repurpose” such mobile 
apps as digital interventions for people living with depression 
and other chronic disorders. Implementation of mHealth 
technologies includes pivotal clinical testing in order to receive 
regulatory approvals and to increase their acceptance among 
patients, primary care providers, and health-care industry, 
including third-party payers. A recent study suggested that 
mobile app intervention was more effective in people with 
moderate depression (44), emphasizing research needs for delin-
eating specific clinical indications, in addition to improving 
clinical efficacy, patient engagement, and long-term effective-
ness. This commentary aims to increase awareness of the medical 
research community and physicians about (1) clinical research 
on non-pharmacological adjunct therapies for depression and 
other CNS disorders and (2) opportunities to integrate non-
pharmacological interventions with self-care using digital health 
technologies, including mobile software becoming medical 
devices.
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